[{"id":"06560225-2b42-48b3-bbbc-b9ae314d8a0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04040231","created_at":"2021-02-01T11:53:19.132Z","updated_at":"2024-07-02T16:34:26.088Z","phase":"Phase 1","brief_title":"Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma","source_id_and_acronym":"NCT04040231","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1","pipe":"","alterations":" ","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Zeltherva (galinpepimut-S) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/24/2019","start_date":" 07/24/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-14"},{"id":"19720944-036d-444d-865d-588a5ff231f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04836429","created_at":"2021-04-08T13:52:42.896Z","updated_at":"2024-07-02T16:34:59.219Z","phase":"Phase 1","brief_title":"Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease","source_id_and_acronym":"NCT04836429","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Photofrin (porfimer sodium)"],"overall_status":"Suspended","enrollment":" Enrollment 16","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 03/17/2025","primary_completion_date":" 03/17/2025","study_txt":" Completion: 03/17/2025","study_completion_date":" 03/17/2025","last_update_posted":"2024-06-04"},{"id":"611fb533-b8fd-4219-b354-66257bca25a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04491942","created_at":"2021-01-18T21:34:47.482Z","updated_at":"2024-07-02T16:34:59.121Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","source_id_and_acronym":"NCT04491942","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • elimusertib (BAY 1895344) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/25/2021","start_date":" 08/25/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"84e4e85b-e9f7-4b35-bc39-067c74a8a32d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05337735","created_at":"2022-04-20T15:53:51.350Z","updated_at":"2024-07-02T16:34:58.974Z","phase":"Phase 2","brief_title":"A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers","source_id_and_acronym":"NCT05337735","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Suspended","enrollment":" Enrollment 140","initiation":"Initiation: 08/05/2022","start_date":" 08/05/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-06-04"},{"id":"a16386f2-e1f8-43e9-a228-a13b2da2c320","acronym":"A082101","url":"https://clinicaltrials.gov/study/NCT05647265","created_at":"2022-12-12T15:00:25.760Z","updated_at":"2024-07-02T16:35:01.662Z","phase":"Phase 2","brief_title":"Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma","source_id_and_acronym":"NCT05647265 - A082101","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-L1 • ALK","pipe":"","alterations":" ","tags":["PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-05-23"},{"id":"67a7cc8f-4495-4593-a5ec-9a4e0b7286d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02414269","created_at":"2021-01-18T11:32:05.371Z","updated_at":"2024-07-02T16:35:02.997Z","phase":"Phase 1/2","brief_title":"Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin","source_id_and_acronym":"NCT02414269","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" MSLN expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • cyclophosphamide intravenous • iCasp9M28z T cell infusion"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-05-17"},{"id":"a72fc2d4-448d-4a6d-b94b-df003ce86195","acronym":"Immuno-MESODEC","url":"https://clinicaltrials.gov/study/NCT05765084","created_at":"2023-03-13T15:02:13.277Z","updated_at":"2024-07-02T16:35:03.321Z","phase":"Phase 1/2","brief_title":"Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma","source_id_and_acronym":"NCT05765084 - Immuno-MESODEC","lead_sponsor":"University Hospital, Antwerp","biomarkers":" WT1","pipe":"","alterations":" ","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/24/2023","start_date":" 02/24/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-16"},{"id":"cd2f0c6b-9287-4ecc-b80c-c18fadf4071e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03074513","created_at":"2021-01-19T13:46:53.660Z","updated_at":"2024-07-02T16:35:03.337Z","phase":"Phase 2","brief_title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","source_id_and_acronym":"NCT03074513","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 03/03/2017","start_date":" 03/03/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-16"},{"id":"07166aaa-56d0-414a-a721-4885a5b98270","acronym":"","url":"https://clinicaltrials.gov/study/NCT02399371","created_at":"2021-01-18T11:26:51.937Z","updated_at":"2024-07-02T16:35:04.256Z","phase":"Phase 2","brief_title":"Pembrolizumab in Treating Patients With Malignant Mesothelioma","source_id_and_acronym":"NCT02399371","lead_sponsor":"University of Chicago","biomarkers":" PD-L1 • CD8","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 03/31/2015","start_date":" 03/31/2015","primary_txt":" Primary completion: 03/20/2026","primary_completion_date":" 03/20/2026","study_txt":" Completion: 03/20/2026","study_completion_date":" 03/20/2026","last_update_posted":"2024-05-13"},{"id":"430c3067-053f-432e-8dd9-54e297aab048","acronym":"","url":"https://clinicaltrials.gov/study/NCT04577326","created_at":"2021-01-29T07:21:30.020Z","updated_at":"2024-07-02T16:35:06.711Z","phase":"Phase 1","brief_title":"Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma","source_id_and_acronym":"NCT04577326","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • ATA2271 • cyclophosphamide intravenous • engineered autologous T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/30/2020","start_date":" 09/30/2020","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-01"},{"id":"e0be9b49-8cbc-4688-a452-7aaedd1a1b20","acronym":"","url":"https://clinicaltrials.gov/study/NCT05228015","created_at":"2022-02-12T17:47:53.327Z","updated_at":"2024-07-02T16:35:09.961Z","phase":"Phase 1","brief_title":"Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05228015","lead_sponsor":"Ikena Oncology","biomarkers":" YAP1 • TFE3 • CAMTA1 • TAFAZZIN","pipe":" | ","alterations":" TFE3 fusion","tags":["YAP1 • TFE3 • CAMTA1 • TAFAZZIN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TFE3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • IK-930"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 01/07/2022","start_date":" 01/07/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-04-12"},{"id":"237b354a-5aa6-4026-9efe-63dba3502553","acronym":"","url":"https://clinicaltrials.gov/study/NCT05451849","created_at":"2022-07-11T11:54:54.962Z","updated_at":"2024-07-02T16:35:16.022Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer","source_id_and_acronym":"NCT05451849","lead_sponsor":"TCR2 Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TC-510"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 06/21/2022","start_date":" 06/21/2022","primary_txt":" Primary completion: 10/30/2028","primary_completion_date":" 10/30/2028","study_txt":" Completion: 10/30/2028","study_completion_date":" 10/30/2028","last_update_posted":"2024-03-06"},{"id":"f8516452-54df-4277-8f56-8aa72d1fb00e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03907852","created_at":"2021-01-18T19:14:14.258Z","updated_at":"2024-07-02T16:35:16.164Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","source_id_and_acronym":"NCT03907852","lead_sponsor":"TCR2 Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 11/02/2028","primary_completion_date":" 11/02/2028","study_txt":" Completion: 11/02/2028","study_completion_date":" 11/02/2028","last_update_posted":"2024-03-06"},{"id":"171fd9a4-54b8-4201-b9ff-abcc3c8df63a","acronym":"NIPU","url":"https://clinicaltrials.gov/study/NCT04300244","created_at":"2024-02-29T19:31:36.820Z","updated_at":"2024-07-02T16:35:17.089Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma","source_id_and_acronym":"NCT04300244 - NIPU","lead_sponsor":"Åslaug Helland","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Leukine (sargramostim) • UV1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 05/04/2020","start_date":" 05/04/2020","primary_txt":" Primary completion: 03/15/2025","primary_completion_date":" 03/15/2025","study_txt":" Completion: 03/15/2027","study_completion_date":" 03/15/2027","last_update_posted":"2024-02-29"},{"id":"77e12794-7dd2-4ce2-bacc-b40dca21f7bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05375825","created_at":"2022-05-17T12:54:06.483Z","updated_at":"2024-07-02T16:35:21.326Z","phase":"Phase 1","brief_title":"Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin","source_id_and_acronym":"NCT05375825","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LMB-100"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 02/06/2024","start_date":" 02/06/2024","primary_txt":" Primary completion: 12/18/2024","primary_completion_date":" 12/18/2024","study_txt":" Completion: 12/18/2024","study_completion_date":" 12/18/2024","last_update_posted":"2024-02-01"},{"id":"22ffb21f-989e-4653-87ef-38c78fadff5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03054298","created_at":"2021-01-18T15:02:34.204Z","updated_at":"2024-07-02T16:35:22.364Z","phase":"Phase 1","brief_title":"CAR T Cells in Mesothelin Expressing Cancers","source_id_and_acronym":"NCT03054298","lead_sponsor":"University of Pennsylvania","biomarkers":" PD-L1","pipe":" | ","alterations":" MSLN expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TmMSTN-01"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 04/06/2017","start_date":" 04/06/2017","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-01-24"},{"id":"aa63f157-3711-446e-8a46-90c1004c4c84","acronym":"SAKK 17/18","url":"https://clinicaltrials.gov/study/NCT04480372","created_at":"2021-01-29T07:20:57.972Z","updated_at":"2024-07-02T16:35:23.233Z","phase":"Phase 2","brief_title":"SAKK 17/18 (ORIGIN) MPM \u0026 NSCLC \u003e1st Line Gemci \u0026 Atezo Ph II","source_id_and_acronym":"NCT04480372 - SAKK 17/18","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • gemcitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-01-17"},{"id":"1709c9a1-ac1e-4f56-aabe-efd83c0933f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126630","created_at":"2021-01-18T15:24:22.600Z","updated_at":"2024-07-02T16:35:23.903Z","phase":"Phase 1/2","brief_title":"Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma","source_id_and_acronym":"NCT03126630","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" PD-L1 expression • MSLN expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 07/08/2023","primary_completion_date":" 07/08/2023","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-01-10"},{"id":"ea9d9a0b-27c4-491d-a445-ee1deb626c7c","acronym":"DREAM3R","url":"https://clinicaltrials.gov/study/NCT04334759","created_at":"2021-01-18T20:59:16.502Z","updated_at":"2024-07-02T16:35:27.393Z","phase":"Phase 3","brief_title":"DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma","source_id_and_acronym":"NCT04334759 - DREAM3R","lead_sponsor":"PrECOG, LLC.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • Imfinzi (durvalumab) • pemetrexed"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 02/18/2021","start_date":" 02/18/2021","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-01"},{"id":"03b258b9-b6b1-4be5-9722-9374ceff289d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03917043","created_at":"2021-09-06T03:53:55.845Z","updated_at":"2024-07-02T16:35:28.475Z","phase":"Phase 1","brief_title":"APG-2449 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03917043","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK positive • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APG-2449"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/27/2019","start_date":" 05/27/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-11-21"},{"id":"41194c64-5b38-487c-8d16-a9a7fa4fe5b1","acronym":"BIMES","url":"https://clinicaltrials.gov/study/NCT05005429","created_at":"2021-08-13T12:53:39.420Z","updated_at":"2024-07-02T16:35:37.791Z","phase":"Phase 2","brief_title":"Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma","source_id_and_acronym":"NCT05005429 - BIMES","lead_sponsor":"Fundación GECP","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 03/30/2025","primary_completion_date":" 03/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2023-09-07"},{"id":"8a6adb38-aff2-48fe-9d34-62af1f2ec96b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05714553","created_at":"2023-06-23T14:09:35.392Z","updated_at":"2024-07-02T16:35:44.820Z","phase":"Phase 1/2","brief_title":"NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT05714553","lead_sponsor":"NuCana plc","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 03/08/2023","start_date":" 03/08/2023","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-06-23"},{"id":"c89a1633-fc10-4b8c-b487-5518baeda827","acronym":"REFIT-MSS","url":"https://clinicaltrials.gov/study/NCT05582031","created_at":"2022-10-17T14:56:48.800Z","updated_at":"2024-07-02T16:35:46.250Z","phase":"Phase 2","brief_title":"Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers","source_id_and_acronym":"NCT05582031 - REFIT-MSS","lead_sponsor":"Translational Research in Oncology","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Stivarga (regorafenib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/30/2023","start_date":" 04/30/2023","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2023-06-07"},{"id":"5d646b6c-e72c-4c25-be57-6c6c7bb08c0a","acronym":"REGOMUNE","url":"https://clinicaltrials.gov/study/NCT03475953","created_at":"2021-01-18T17:07:36.724Z","updated_at":"2024-07-02T16:35:54.106Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","source_id_and_acronym":"NCT03475953 - REGOMUNE","lead_sponsor":"Institut Bergonié","biomarkers":" PD-L1 • BRAF • ALK • TMB • MSI • ROS1 • CTLA4","pipe":" | ","alterations":" TMB-H • ALK positive • ALK mutation • ROS1 positive","tags":["PD-L1 • BRAF • ALK • TMB • MSI • ROS1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • ALK positive • ALK mutation • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 747","initiation":"Initiation: 05/04/2018","start_date":" 05/04/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-03-03"}]